Pembrolizumab versus Ipilimumab in Advanced Melanoma.

By C. Robert, J. Schachter, Georgina V. Long, A. Arance, J. Grob, L. Mortier, A. Daud, M. Carlino, C. McNeil, M. Lotem and 12 more. New England Journal of Medicine, 2015

5,305 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/0dac3ea80083f0a86598cb9af0a205554280551b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Oncology

Citations in the corpus

Primary resistance to PD-1 blockade mediated by JAK1/2 mutations (2016, background): “Blocking the programmed death 1 (PD-1) negative immune receptor results in unprecedented rates of long lasting anti-tumor activity in patients with metastatic cancers of different histologies, including melanoma, Hodgkin’s disease, Merkel cell, head and neck, lung, esophageal, gastric, liver, kidney”
Defining T cell states associated with response to checkpoint immunotherapy in melanoma (2018, neutral): “Although immune checkpoint blockade leads to durable responses in patients with metastatic melanoma, refractory disease and progression after initial response remain major causes of mortality (Larkin et al., 2015; Robert et al., 2015).”
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “5–2 times more frequent, in patients receiving anti-PD-1 therapy compared with ipilimumab monotherapy, as reported across several melanoma trials [12].”
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy (2018, background): “4B), with enrichment among patients with tumors that are generally more responsive to pembrolizumab, such as melanoma and NSCLC (25, 26), and underrepresentation among patients with tumors such as prostate cancer and glioblastoma that are typically more resistant to immunotherapy (27, 28).”
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. (2015, neutral): “These findings are consistent with clinical observations that anti-PD therapy has low autoimmune toxicity (50).”
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018, background): “Severe adverse reactions include severe diarrhea, colitis, increased alanine aminotransferase levels, inflammation pneumonitis, and interstitial nephritis (67, 73, 99).”
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019, methodology): “Based on very recent randomised trial results, comparing anti-PD1 antibody therapies to ipilimumab, anti-PD1 antibody therapy is the preferred first-line treatment of patients with BRAF-wt disease [42].”